Riesgo de acidosis láctica fatal y no fatal con el uso de metformina para la diabetes mellitus tipo 2
Characteristics of included studies Notes Allocation concealment
D
Study
Menzies 1989
Methods
TRIAL DESIGN: Prospective cohort study DURATION: 3 months
Participants
COUNTRY: United Kingdom SETTING: outpatient Treatment N: 64 Control N: 0 AGE: 64+/-9 SEX: 41% men INCLUSION: obese patients with type 2 DM EXCLUSIONS: ketosis, or abnormal electrolytes or renal function
Interventions
TREATMENT: Metformin 1.5-2 g/day or 2.5-3 g/day COMPARISON: none
Outcomes
Plasma glucose, HbA1, and lactate.
Notes Allocation concealment
D
Study
Moses 1999a
Methods
TRIAL DESIGN: Double-blind randomised controlled trial DURATION: 22 weeks
Participants
COUNTRY: Australia SETTING: outpatient Treatment N: 54 Control N: 28 Treatment AGE: 57.8 Control AGE: 60.3 Treatment SEX: 63% men Control SEX: 54% men INCLUSION: Type 2 DM with poor control on metformin EXCLUSIONS: clincally significant renal insufficiency, abnormal liver functions, cardiac diasease, history of lactic acidosis
Interventions
TREATMENT: Metformin, dosage adjusted clinically, + placebo; or metformin + repaglinide COMPARISON: repaglinide + placebo
Outcomes
Fasting glucose, and HbA1.
Notes Allocation concealment
D
Study
Munk 1975
Methods
TRIAL DESIGN: Open-label comparative trial TRIAL DURATION: 6 months
Página 74
Copyright © John Wiley & Sons Ltd. Usado con permiso de John Wiley & Sons, Ltd.